Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control

BACKGROUND: Sulfonylureas (SUs) are commonly used in the treatment of type 2 diabetes (T2DM), usually as second-line treatment after the failure of metformin. However, SUs are associated with poor durability, hypoglycemia and weight gain. Empagliflozin is a sodium glucose cotransporter 2 (SGLT2) inh...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Ridderstråle, Martin, Svaerd, Robbyna, Zeller, Cordula, Kim, Gabriel, Woerle, Hans J, Broedl, Uli C
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2013
נושאים:
Study Protocol
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3844307/
https://ncbi.nlm.nih.gov/pubmed/24007456
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1475-2840-12-129
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים